Gerry is a commercial and intellectual property partner with over 25 years’ experience gained in senior in-house and advisory roles across multiple sectors. Prior to joining Keystone, Gerry served as the UK General Counsel for Lonza, a global supplier to the pharmaceutical, biotech, and specialty ingredients industries.
Gerry specialises specifically in the life sciences sector, where he has spent more than two decades advising on complex commercial, intellectual property, and technology matters. He is experienced in negotiating development and manufacturing agreements, overseeing international manufacturing projects, advising on gene expression technology licensing, and supporting clients with research and collaboration agreements.
His clients include multinational pharmaceutical companies and early-stage biotech businesses.
Expertise
Gerry advises on complex commercial agreements, including development, manufacturing, supply, and R&D collaborations. He has extensive experience negotiating cross-border contracts for multinationals and start-ups across highly regulated and technical industries.
Experience
Advised on multiple large-scale biologics’ manufacturing agreements across different facilities worldwide.
Advised on product development agreements, encompassing specification targets, raw material supplies, and quality agreements.
Advised on joint venture agreements for the manufacture of biosimilars and for shared manufacturing facilities.
Gerry advises on protecting and exploiting intellectual property in commercial and collaborative settings. His experience includes IP strategy, ownership, and structuring agreements to safeguard and leverage innovation in international projects.
Experience
Advised on the creation of a royalty monetisation programme.
Advised on the protection of know-how used in the development of manufacturing processes.
Advised on collaboration agreements with pharma companies and the appropriate allocation of IP.
Gerry specialises in technology and product licensing, with particular expertise in biologics. He has negotiated global licensing of proprietary systems, technology transfer arrangements, and collaboration agreements involving universities, start-ups and pharma.
Experience
Advised a large engineering company on trade-mark licensing agreements in the automotive sector.
Advised on out-licensing agreements for pharmaceutical manufacturing processes.
Advised a large pharmaceutical manufacturer on a technology collaboration agreement with a commercial customer.
Advised a pharmaceutical company on a research & development agreement with an American University.
With over 20years in life sciences, Gerry advises on biopharmaceutical development, manufacturing, and collaborations. He acts for pharmaceutical companies, biotech businesses, and research organisations, principally in relation to biologics, small molecules, and cell & gene therapies.
Experience
Advised on numerous biopharmaceutical Development and Manufacturing Services Agreements (DMSAs) and the accompanying Quality Agreement.
Advised on regulatory matters relating to biopharmaceutical facility inspections by the FDA, MHRA, and other regulatory bodies.
Advised on a joint venture established for the global manufacture of biosimilars.
Advised on the sale of a large-scale pharmaceutical manufacturing facility in Singapore.
Advised on the purchase of a large-scale pharmaceutical manufacturing facility in Spain.
Advised a pharmaceutical manufacturer on a technology collaboration agreement with a commercial customer.
Advised on numerous patent and know-how licences relating to cell lines.
Advised on the creation of a royalty monetisation programme.
Please note: The experience list above may include examples of work completed prior to joining Keystone Law.
Recognition
Chairman of the Thomson Reuters 3rd Annual Life Sciences Law Forum
Member of the Pharmaceutical Licensing Group (PLG)
Gerry qualified as a solicitor in 1991. Prior to joining Keystone Law in 2025, he worked at the following firms:
